[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"recurrent-aphthous-stomatitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:recurrent-aphthous-stomatitis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,76,108],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100648467","the-preventive-and-therapeutic-effects-of-spirulina-preparations-on-ulcers-of-oral-mucosa-100648467",false,"NCT07723612","The Preventive and Therapeutic Effects of Spirulina Preparations on Ulcers of Oral Mucosa","The Preventive and Therapeutic Effects of Spirulina Preparations on Recurrent Aphthous Ulcers of the Oral Mucosa","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Patients with radiation-induced oral mucositis (RIOM), recurrent aphthous stomatitis (RAS), or other clinically diagnosed oral ulcers, confirmed by clinical examination.\n* Presence of at least one clinically active oral ulcer at the time of enrollment.\n* Able to understand the study procedures and provide written informed consent.\n* Willing and able to comply with all study procedures, follow-up visits, and assessments.\n\nExclusion Criteria:\n\n* Previous radiotherapy to the head and neck region.\n\n  * Known allergy or hypersensitivity to spirulina or its components.\n  * Severe hepatic, renal, cardiovascular, or other uncontrolled systemic diseases.\n  * Pregnancy or breastfeeding.\n  * Participation in another interventional clinical trial during the study period.\n  * Any condition that, in the investigator's opinion, would interfere with study participation or outcome assessment.","ALL","18 Years","100 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a prospective, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the efficacy and safety of spirulina supplementation in patients with radiation-induced oral mucositis (RIOM) receiving radiotherapy for head and neck cancer. Participants will be randomly assigned to receive either spirulina tablets or placebo in addition to standard oral care during radiotherapy. The primary objective is to determine whether spirulina reduces the severity of oral mucositis. Secondary outcomes include the incidence and duration of severe oral mucositis, oral pain, nutritional status, quality of life, treatment interruption, and adverse events. The findings of this study may provide evidence for an effective and safe adjunctive intervention to improve the management of radiation-induced oral mucositis and enhance the quality of life of patients undergoing radiotherapy.",[27,28],"Recurrent Aphthous Stomatitis","Mouth Ulcer",[30],"Radiation-induced oral mucositis Recurrent aphthous stomatitis Oral ulcer Spirulina Oral microbiota Saliva biomarkers Supportive care","RECRUITING","2026-07-21",{"date":34,"type":35},"2026-07-23","ACTUAL",{"date":37,"type":35},"2026-06-01",{"date":39,"type":21},"2028-07-01",{"name":41,"class":42},"The Fourth Affiliated Hospital of Zhejiang University School of Medicine","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":61,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":4},"100648199","improving-prescribing-quality-for-oral-mucosal-disorders-using-a-pharmacist-led-model-100648199","NCT07721090","Improving Prescribing Quality for Oral Mucosal Disorders Using a Pharmacist-Led Model","Pharmacological Management Optimization for Oral Mucosal Disorders: A Clinical Pharmacist Led Cluster Randomized Controlled Trial With Implementation Science Evaluation","Inclusion Criteria:\n\n* Adults aged 18 years and above\n* Diagnosed with an oral mucosal disorder (oral lichen planus, recurrent aphthous stomatitis, burning mouth syndrome, Herpes viral infection or oral candidiasis)\n* Attending participating dental clinic sessions during the study period\n* Prescribed pharmacological treatment for the oral mucosal condition\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* Patients without a confirmed diagnosis of an oral mucosal disorder\n* Patients requiring immediate emergency care or hospitalization\n* Patients currently enrolled in another interventional clinical trial\n* Known hypersensitivity to commonly prescribed medications used in the study\n* Patients unable to comply with follow-up or study procedures","70 Years",{"count":53,"type":21},336,[24],"This study aims to improve how oral mucosal disorders-such as oral lichen planus, recurrent aphthous stomatitis, burning mouth syndrome, herpes viral infection and oral candidiasis-are treated in dental settings. A pharmacist will work with dentists to review prescriptions, provide feedback, counsel patients, and monitor medication safety. Dental clinics will be assigned to either the pharmacist-led model or usual care. The study will evaluate whether this approach improves prescribing quality, patient adherence, symptom control, and safety. The findings may help establish a more standardized, effective way to manage these common oral conditions in routine dental practice.",[57,27,58,59,60],"Oral Lichen Planus","Burning Mouth Syndrome","Oral Candidiasis","Herpes Virus Infection",[62,57,27,58,59,63,64,65],"Oral Mucosal Diseases","Medication Therapy Management","Drug Prescriptions","Patient Compliance","NOT_YET_RECRUITING","2026-07-19",{"date":69,"type":35},"2026-07-22",{"date":71,"type":21},"2026-07-01",{"date":73,"type":21},"2027-12-31",{"name":75,"class":42},"University of Fujairah",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":83,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":43},"100603841","salivary-e-cadherin-calprotectin-and-matrix-metalloproteinase-9-levels-in-recurrent-aphthous-stomatitis-100603841","NCT07141758","Salivary E-cadherin, Calprotectin, and Matrix Metalloproteinase-9 Levels in Recurrent Aphthous Stomatitis","Investigation of Salivary E-cadherin, Calprotectin, and Matrix Metalloproteinase-9 Levels in Patients With Recurrent Aphthous Stomatitis","Inclusion Criteria:\n\n* Participants aged 18 years or older\n* Clinically diagnosed with minor recurrent aphthous stomatitis (RAS) (defined as having a history of at least three RAS episodes within the past year)\n* Systemically healthy (i.e., without any diagnosed systemic disease)\n* No history of tobacco use\n* Presence of at least one active aphthous ulcer at the time of saliva sample collection\n* No known mental or physical disabilities\n\nExclusion Criteria:\n\n* Use of any pharmacological treatment within the past 3 months\n* Use of antiseptic mouthwash within the past 3 months\n* Pregnant or lactating individuals, or those currently using oral contraceptives\n* History of systemic diseases associated with oral ulcerations such as Crohn's disease, ulcerative colitis, celiac disease, or Behçet's disease\n* History of chemotherapy or radiotherapy\n* Current or prior use of immunomodulatory drugs, cytotoxic agents, or systemic corticosteroids\n* Undergoing orthodontic treatment (to avoid misdiagnosis with traumatic ulcers)\n* Use of removable dental prostheses (to avoid misdiagnosis with traumatic ulcers)\n* Presence of periodontal disease (CPI score of 3 or 4)\n* Caries risk not classified as very low (DMFT ≥ 5)\n* Presence of pathological oral mucosal lesions such as lichen planus, pemphigus vulgaris, or mucous membrane pemphigoid",true,{"count":85,"type":21},102,"OBSERVATIONAL","The goal of this observational cross-sectional study is to determine the salivary levels of E-cadherin, Calprotectin, and Matrix Metalloproteinase-9 (MMP-9) in patients with Recurrent Aphthous Stomatitis (RAS) and to compare them with those of healthy controls.\n\nThe main questions it aims to answer are:\n\nAre the salivary levels of E-cadherin, Calprotectin, and MMP-9 significantly different in patients with minor RAS compared to healthy controls?\n\nCan these salivary proteins serve as biomarkers involved in the pathogenesis of minor RAS?\n\nResearchers will compare patients with minor RAS and healthy individuals to determine whether differences in salivary E-cadherin, Calprotectin, and MMP-9 levels are associated with the presence of disease.\n\nParticipants will:\n\nProvide unstimulated saliva samples using a saliva swab\n\nUndergo clinical evaluation for periodontal status (Community Periodontal Index - CPI) and caries experience (DMFT index)\n\nCollected saliva samples will be stored at -80°C until analysis. The concentrations of the investigated proteins will be measured using ELISA kits, and total protein levels will be determined using a colorimetric protein assay.\n\nThe relationships among the salivary concentrations of the investigated proteins, as well as their associations with demographic variables such as age and sex, will be analyzed.",[27,89],"Aphthous Ulcer",[91,92,93,94,95,96,97,98],"E-cadherin","Calprotectin","MMP-9","ELISA","Recurrent aphthous stomatitis","RAS","Saliva","Salivary Biomarkers","2025-08-25",{"date":101,"type":35},"2025-08-26",{"date":103,"type":35},"2025-04-10",{"date":105,"type":21},"2026-06-30",{"name":107,"class":42},"Selin Yeşiltepe",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":22,"phases":118,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":4},"100592431","phase-2-effect-of-topical-bromelain-versus-topical-corticosteroids-in-the-management-of-recurrent-aphthous-stomatitis-100592431","NCT06993337","Effect of Topical Bromelain Versus Topical Corticosteroids in the Management of Recurrent Aphthous Stomatitis","Evaluation of Topical Bromelain Versus Topical Corticosteroids in Management of Recurrent Aphthous Stomatitis: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults aged 18-60 years.\n* Diagnosed with RAS.\n* Onset of ulcer within the last 48 hours.\n* Willingness to participate and provide informed consent.\n\nExclusion Criteria:\n\n* History of hematological deficiencies, GIT disorders, Behcet's disease and major systemic diseases.\n* Pregnant or breastfeeding patients.\n* Previous treatment for the current ulcer episode.","60 Years",{"count":117,"type":21},63,[119],"PHASE2","Bromelain, a natural product, exhibits anti-inflammatory, immunomodulatory, and wound-healing properties. However, its efficacy in treating oral mucosal ulcers remains unexplored. This study aims to evaluate the effect of bromelain as a safe alternate for management of RAS.",[27],"2025-05-25",{"date":124,"type":35},"2025-05-28",{"date":126,"type":21},"2025-06-15",{"date":128,"type":21},"2026-06-15",{"name":130,"class":42},"Cairo University"]